HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19 Claims for OTC Intravenous Drips Found In Advertising On Both Sides Of Atlantic

Executive Summary

UK agency advises two medical spas to discontinue claims suggesting IV drips prevent or cure COVID-19. In separate rulings to the companies, ASA notes the UK MHRA says including COVID-19 in promotions would bring the IV drips under medicines regulation.

You may also be interested in...



US COVID-19 Fraud: FTC Points To Peptides As Latest Scam, Silver Remedy Firm Shut Down

FTC warns 20 firms selling products or services promising to prevent or treat COVID-19, including three clinics saying peptides help boost the effectiveness of a vaccine. NJ business promoting collodial silver to prevent or treat novel coronavirus infection shut down in a DoJ complaint after failing to comply with regulatory agencies' warning.

Anemia Patients’ Iron Absorption Doesn’t Improve With Vitamin C Supplementation – Study

Patients with iron deficiency anemia do not benefit from pairing iron supplementation with vitamin C, according to an RCT that found no significant change in hemoglobin level between a group of subjects taking iron/vitamin C and those taking just iron. 

US Hospitals’ COVID-19 Treatment Protocols Aren’t Prescriptions To Make Vitamin C Ad Claims

Marketer of Billy’s Infinity-C supplement line discontinues social media post that COVID-19 patients in hospitals are receiving high doses of vitamin C. BBB National Programs division says the post implies consumers can prevent contracting the virus through vitamin C use. 

Related Content

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel